We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 31, 2019

Olaparib vs Chemotherapy in Patients With a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
OlympiAD Final Overall Survival and Tolerability Results: Olaparib Versus Chemotherapy Treatment of Physician’s Choice in Patients With a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer
Ann. Oncol 2019 Jan 23;[EPub Ahead of Print], ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, S Delaloge, W Li, A Armstrong, W Wu, C Goessl, S Runswick, SM Domchek

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading